Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Operating Expenses (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Operating Expenses for 8 consecutive years, with $21.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 14.86% to $21.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.4 million through Dec 2025, down 8.9% year-over-year, with the annual reading at $86.4 million for FY2025, 8.9% down from the prior year.
  • Operating Expenses for Q4 2025 was $21.7 million at Precision Biosciences, up from $20.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $47.2 million in Q2 2021, with the low at $20.7 million in Q3 2025.
  • Average Operating Expenses over 5 years is $26.9 million, with a median of $22.8 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 39.21% in 2021, then crashed 38.73% in 2022.
  • Over 5 years, Operating Expenses stood at $37.1 million in 2021, then plummeted by 38.73% to $22.7 million in 2022, then dropped by 3.43% to $21.9 million in 2023, then increased by 16.22% to $25.5 million in 2024, then fell by 14.86% to $21.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $21.7 million, $20.7 million, and $21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.